Ironwood Pharmaceuticals, Inc.IRWDNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
69.84%
↑ 194% above average
Average (39q)
-73.93%
Historical baseline
Range
High:880.07%
Low:-2423.55%
CAGR
-0.0%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 69.84% |
| Q2 2025 | 163.12% |
| Q1 2025 | -1757.18% |
| Q4 2024 | -38.12% |
| Q3 2024 | 523.95% |
| Q2 2024 | 79.34% |
| Q1 2024 | -282.89% |
| Q4 2023 | -107.09% |
| Q3 2023 | 101.44% |
| Q2 2023 | -2423.55% |
| Q1 2023 | -6.45% |
| Q4 2022 | -2.88% |
| Q3 2022 | 35.70% |
| Q2 2022 | -4.44% |
| Q1 2022 | -6.22% |
| Q4 2021 | -25.91% |
| Q3 2021 | -85.73% |
| Q2 2021 | 880.07% |
| Q1 2021 | -7.59% |
| Q4 2020 | 25.51% |
| Q3 2020 | 36.58% |
| Q2 2020 | 653.48% |
| Q1 2020 | -93.01% |
| Q4 2019 | 131.78% |
| Q3 2019 | 68.10% |
| Q2 2019 | 120.72% |
| Q1 2019 | -282.65% |
| Q4 2018 | 91.11% |
| Q3 2018 | -253.08% |
| Q2 2018 | -14.45% |
| Q1 2018 | -457.00% |
| Q4 2017 | 137.42% |
| Q3 2017 | 26.97% |
| Q2 2017 | 15.77% |
| Q1 2017 | -288.75% |
| Q4 2016 | 59.33% |
| Q3 2016 | -53.00% |
| Q2 2016 | -63.21% |
| Q1 2016 | 5.27% |
| Q4 2015 | 70.38% |